The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  • Email Email
  • Glossary Glossary


Dec 23, 2001

Goodmorning, I would like to know if you think a new PI under development called Tipranavir will be able to get aproval in 2003? I have read that it is very effective against a large number of resistant virus mutants. This would of course be wonderful news! But I have also been told by those who have followed it that it has some really nasty side effects especially gastrointestinal. It has also not been looked at as a once a day PI. I wanted to know if you thought that it might be able to be reformulated to allow for daily dosage and to eliminate the nasty side effects?

Response from Dr. Boyle

I think that approval for tipranvir in 2003 is a reasonable time frame. Based upon the pK data I have seen to date, I doubt that they will be able to formulate it to a once daily medication, but I know that the pharmaceutical companies are working on this very hard so I might be surprised.

Extended release AZT
How long before side effects go away?

  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint